Title: New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Volume: 11
Issue: 6
Author(s): L. Laurenti, L. De Padua, G. D'Arena, B. Vannata, I. Innocenti, M. Tarnani, S. Deaglio, S. Sica, D. G. Efremov and G. Leone
Affiliation:
Keywords:
CD20, CD23, CD37, CD40, CD52, chronic lymphocytic leukemia, monoclonal antibodies, preclinical, CLL, alemtuzumab, rituximab, mAbs
Abstract: Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.
